The oral drug against covid-19 molnupiravir eliminates the actively infectious SARS-Cov-2 virus on the third day of starting therapy, according to a study to be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). (Keep reading: The BA.2 sublineage already accounts for more than half of the cases in the US.)However, “many … Read more
Updated on 02/17/2022 02:20 pm Today Digemid issued the conditional sanitary registration of Molnupiravir, thus allowing the commercialization of the oral treatment developed by the pharmaceutical company Merck Sharp & Dohmeaimed at treating mild and moderate cases of COVID. The pharmaceutical company -through a statement- explained that the drug “has demonstrated efficacy and safety in … Read more
The American laboratory Merck estimated that this year it will obtain up to USD 6,000 million in sales of its pill against coronavirus (COVID-19), molnupiravir, according to a financial report published on Thursday. The US pharmaceutical company said it generated $952 million from the sale of its oral COVID-19 pill in the fourth quarter of … Read more